Sio Gene Therapies Inc (SIOX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access SIOX Annual Balance Sheets →
Examining balance sheet movements between Sio Gene Therapies Inc and Dec 31 2021 reveals how Dec 31 2022 adjusts its asset composition and liability profile.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2022)
(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent46.13
Cash & Short-term Investments46.00
Income Taxes Receivable, Current NO0.36
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.79
Total Current Assets47.27
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Restricted Cash Current0.00
Operating Lease Right Of Use Asset-
Total Assets47.27
Liabilities
Accounts Payable, Current AC0.20
Accrued Liabilities, Current AC1.95
Other Liabilities, Current0.00
Total Current Liabilities2.15
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current-
Operating Lease Liability Noncurrent-
Total Liabilities2.15
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock923.25
Retained Earnings / Accumulated Deficit-878.46
Other Equity0.33
Common Stockholder's Equity45.12
Total Stockholder's Equity45.12
Liabilities & Stockholder's Equity47.27
4 historic quarters locked

Sign in to unlock the full Sio Gene Therapies Inc balance sheet history.

About Sio Gene Therapies Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001636050-23-000007

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.